Current approaches to antiarrhythmic therapy in heart failure
Lisa J Rose-Jones1, Weeranun D Bode2, Anil K Gehi3
1Advanced Heart Failure & Pulmonary Hypertension, UNC Heart & Vascular Center, 6th Floor, Burnett-Womack Building, 160 Dental Circle, CB#7075, Chapel Hill, NC 27599, USA.
Heart Failure Clinics
|September 14, 2014
Summary
Atrial fibrillation (AF) and heart failure (HF) often coexist. For symptomatic AF in HF patients, restoring normal heart rhythm is key, and antiarrhythmic drugs are vital for managing ventricular arrhythmias and preventing defibrillator shocks.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Atrial fibrillation (AF) frequently occurs in heart failure (HF) patients due to shared risk factors.
- Ventricular arrhythmias are a leading cause of death in patients with NYHA class I-III HF.
- Implantable cardioverter defibrillators (ICDs) reduce sudden cardiac arrest but do not eliminate ventricular tachycardia (VT) or ICD shocks.
Purpose of the Study:
- To review the management of atrial fibrillation in heart failure patients.
- To highlight the importance of rhythm control in specific AF patient populations.
- To discuss the role of antiarrhythmic drugs in managing ventricular arrhythmias in HF.
Main Methods:
- Literature review of studies on AF and HF management.
- Analysis of treatment strategies for rate and rhythm control in AF.
- Evaluation of antiarrhythmic drug efficacy for VT and ICD shock prevention.
Main Results:
- Rate control is standard for AF in HF, but rhythm restoration is indicated for symptomatic patients.
- Antiarrhythmic drug therapy, beyond beta-blockers, is crucial for terminating acute VT.
- Pharmacological interventions are fundamental in preventing recurrent VT and ICD shocks.
Conclusions:
- Integrated management of AF and HF is essential.
- Rhythm control strategies should be considered for symptomatic AF in HF.
- Antiarrhythmic drugs play a critical role in managing life-threatening ventricular arrhythmias in HF patients.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
626
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
626
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:25Dysrhythmias VI: Management of Dysrhythmias
593
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
593
01:30Heart Failure V: Medical Management
611
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
611
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.6K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.6K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K